High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector

Высокоуровневая экспрессия мономерного RBD 320–537 S-белка SARS-CoV-2 в стабильно трансфицированных клетках CHO с использованием плазмидного вектора на основе EEF1A1
Maria V. Sinegubova, Н. А. Орлова, С. В. Ковнир, Lutsia K. Dayanova, I. I. Vorobiev
2021-02-02

CHO cell expressionEEF1A1-based plasmid vectorN-glycosylationSARS-CoV-2 receptor-binding domainSerological tests
The spike (S) protein is one of the three proteins forming the coronaviruses' viral envelope. The S protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has a spatial structure similar to the S proteins of other mammalian coronaviruses, except for a unique receptor-binding domain (RBD), which is a significant inducer of host immune response. Recombinant SARS-CoV-2 RBD is widely used as a highly specific minimal antigen for serological tests. Correct exposure of antigenic determinants has a significant impact on the accuracy of such tests-the antigen has to be correctly folded, contain no potentially antigenic non-vertebrate glycans, and, preferably, should have a glycosylation pattern similar to the native S protein. Based on the previously developed p1.1 vector, containing the regulatory sequences of the Eukaryotic translation elongation factor 1 alpha gene (EEF1A1) from Chinese hamster, we created two expression constructs encoding SARS-CoV-2 RBD with C-terminal c-myc and polyhistidine tags. RBDv1 contained a native viral signal peptide, RBDv2 -human tPA signal peptide. We transfected a CHO DG44 cell line, selected stably transfected cells, and performed a few rounds of methotrexate-driven amplification of the genetic cassette in the genome. For the RBDv2 variant, a high-yield clonal producer cell line was obtained. We developed a simple purification scheme that consistently yielded up to 30 mg of RBD protein per liter of the simple shake flask cell culture. Purified proteins were analyzed by polyacrylamide gel electrophoresis in reducing and non-reducing conditions and gel filtration; for RBDv2 protein, the monomeric form content exceeded 90% for several series. Deglycosylation with PNGase F and mass spectrometry confirmed the presence of N-glycosylation. The antigen produced by the described technique is suitable for serological tests and subunit vaccine studies.
1
A simple purification process yielded up to 30 mg of recombinant RBD per liter of shake-flask culture.
2
An EEF1A1-based plasmid vector enabled stable expression of SARS-CoV-2 RBD variants in CHO DG44 cells after methotrexate-driven genomic amplification.
3
PNGase F treatment and mass spectrometry confirmed N-glycosylation, supporting the antigen’s use in serological assays and subunit vaccine studies.
4
Purified RBDv2 was predominantly monomeric, with monomer content exceeding 90% in several production series.
5
Using a human tPA signal peptide, the RBDv2 construct produced a high-yield clonal CHO cell line, outperforming the native viral signal-peptide variant in production outcome.

Monomeric recombinant SARS-CoV-2 spike protein receptor-binding domain (RBD 320–537) produced in stably transfected CHO cells

High-level expression, glycosylation, monomeric content, and suitability as a serological-test and subunit-vaccine antigen

Publication Details
Publication Date
2021-02-02
Journal
Publisher
ISSN
Cited by
40
Access Type
Author Information
Authors
Maria V. Sinegubova
Н. А. Орлова
С. В. Ковнир
Lutsia K. Dayanova
I. I. Vorobiev
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%